The application of pharmacogenetics in identifying single nucleotide polymorphisms (SNPs) in DNA sequences that cause clinically significant alterations in drug-metabolizing enzyme activities is discussed. Recent advances in pharmacogenomic research have begun to elucidate the inherited nature of interindividual differences in drug-induced adverse reactions, toxicity, and therapeutic responses. In one particular area of study, variations in DNA sequences (i.e., genetic polymorphisms) explain some of the variability in drug-metabolizing enzyme activities which contribute to alterations in drug clearance and impact patients' response to drug therapy. Historical and current examples of several extensively studied SNPs include the genes encoding for glucose-6-phosphate dehydrogenase, N-acetyltransferase, and the superfamily of cytochrome P-450 (CYP) isoenzymes. Because CYP isoenzymes metabolize a large number of structurally diverse drugs and chemicals, most of the variant genotypes of the CYP2D6, CYP2C9, CYP2C19, and CYP3A families have been identified and studied. Individuals with aberrant genes for these enzymes may experience diminished efficacy or increased toxicity in response to certain drugs because of the different levels of activities associated with variant genotypes. The frequency of variant alleles for drug-metabolizing enzymes often differs among ethnic groups. Continued research in pharmacogenetics will further our understanding in interindividual differences in drug disposition. The application of this knowledge will ultimately help individualize drug dosing and drug therapy selection, predict toxicity or therapeutic failure, and improve clinical outcomes. Pharmacogenetics has elucidated the genetic basis for interindividual variability in drug response and will continue to play a key role in defining strategies to optimize drug therapy.

 

This article has been cited by other articles:

				K. W. Phillips, P. P. Dobesh, and S. T. Haines Considerations in using anticoagulant therapy in special patient populations Am. J. Health Syst. Pharm., August 1, 2008; 65(15_Supplement_7): S13 - S21. [Abstract] [Full Text] [PDF]

				Amal Al Omari and D. J. Murry Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical Significance Journal of Pharmacy Practice, June 1, 2007; 20(3): 206 - 218. [Abstract] [PDF]

				Y. M. Kim, S. H. Yoo, R. Y. Kang, M. J. Kim, Y. Y. Bae, Y. K. Lee, S. J. Jeon, K. J. Chon, S. M. Shin, S. G. Kim, et al. Identifying drugs needing pharmacogenetic monitoring in a Korean hospital Am. J. Health Syst. Pharm., January 15, 2007; 64(2): 166 - 175. [Abstract] [Full Text] [PDF]

				J. Meletiadis, S. Chanock, and T. J. Walsh Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy Clin. Microbiol. Rev., October 1, 2006; 19(4): 763 - 787. [Abstract] [Full Text] [PDF]

				S. Bernard, K. A. Neville, A. T. Nguyen, and D. A. Flockhart Interethnic Differences in Genetic Polymorphisms of CYP2D6 in the U.S. Population: Clinical Implications. Oncologist, February 1, 2006; 11(2): 126 - 135. [Abstract] [Full Text] [PDF]

				M. G. Tyshenko and W. Leiss Current trends in publicly available genetic databases Health Informatics Journal, December 1, 2005; 11(4): 295 - 308. [Abstract] [PDF]

				K. Kim, J. A. Johnson, and H. Derendorf Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms J. Clin. Pharmacol., October 1, 2004; 44(10): 1083 - 1105. [Abstract] [Full Text] [PDF]

				J. E. Aldridge, J. A. Gibbons, M. M. Flaherty, M. L. Kreider, J. A. Romano, and E. D. Levin Heterogeneity of Toxicant Response: Sources of Human Variability Toxicol. Sci., November 1, 2003; 76(1): 3 - 20. [Abstract] [Full Text] [PDF]

				W. E Dager Initiating Warfarin Therapy Ann. Pharmacother., June 1, 2003; 37(6): 905 - 908. [Full Text] [PDF]